Abstract
Objective: The phase 3 VELIA trial demonstrated that veliparib dosed concurrently with carboplatin/paclitaxel and continued as maintenance monotherapy resulted in a statistically significant improvement in progression-free survival compared to carboplatin/paclitaxe alone in patients with newly diagnosed stage III–IV high-grade serous ovarian, fallopian tube, and peritoneal cancer. It has been hypothesized that while DNA repair deficiencies may improve response to PARP inhibition, they may also render patients with BRCA mutations (BRCAm) or homologous recombination-deficient (HRD) tumors more sensitive to treatment-related toxicities.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have